Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses
- 3 November 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 2 (12) , 2324-2332
Abstract
Subunit vaccines provide a safe, focused alternative to conventional vaccines. However, these vaccines often require significant adjuvants and are particularly hard to target toward cytotoxic T lymphocyte (CTL) immunity. Viruslike particles (VLPs) provide biomaterial scaffolds with pathogen-like polyvalent structures making them useful platforms for biomimetic antigen delivery to the immune system. Encapsidation of antigens within VLPs has been shown to enhance antigen availability for CD8 T cell responses. Here, we examine the potential to generate complex responses to multiple subunit antigens localized within the same VLP particle. Two proteins of respiratory syncytial virus (RSV) with well-characterized CD8 T cell responses, the matrix (M) and matrix 2 (M2) proteins, were successfully coencapsidated within the P22 VLP. Upon intranasal administration in mice, the particles stimulated CD8 T cell memory responses against both antigens. In addition, vaccination elicited tissue-resident T cell populations. Upon subsequent RSV challenge, P22-M/M2-treated mice displayed significantly reduced lung viral titers. This demonstrates the utility of the P22 VLP in directing immune responses to multiple encapsidated viral antigens, demonstrating the potential of this technology to facilitate immunity to multiple targets simultaneously.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI104905)
- National Institute of Biomedical Imaging and Bioengineering (R01 EB012027)
This publication has 53 references indexed in Scilit:
- Sensing and alarm function of resident memory CD8+ T cellsNature Immunology, 2013
- Vaccines against malariaPhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in MiceThe Journal of Infectious Diseases, 2011
- Biological challenges and technological opportunities for respiratory syncytial virus vaccine developmentImmunological Reviews, 2010
- Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccinationMucosal Immunology, 2010
- Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory VirusesPLOS ONE, 2009
- Characterization of Respiratory Syncytial Virus M- and M2-Specific CD4 T Cells in a Murine ModelJournal of Virology, 2009
- Viral and Host Factors in Human Respiratory Syncytial Virus PathogenesisJournal of Virology, 2008
- Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infectionVirology, 2007
- Prophylactic human papillomavirus vaccinesJournal of Clinical Investigation, 2006